Remedy Pharmaceuticals, Inc. Announces Appointment Of Chief Financial Officer

NEW YORK--(BUSINESS WIRE)--Remedy Pharmaceuticals, a clinical stage pharmaceutical company focused on the development and commercialization of a revolutionary, breakthrough drug, CIRARA™, for treating acute central nervous system conditions — where there are inadequate or no approved existing therapies — announced today the appointment of Richard I. Steinhart as Chief Financial Officer effective immediately.

Suggested Articles

Almirall is pulling the trigger on an option to advance Dermira's lebrikizumab in Europe, a program it reckons could rake in €450 million.

Acer Therapeutics’ stock plummeted more than 78% premarket this morning on news that the FDA had rejected approval of its drug Edsivo (celiprolol).

The latest setback prompted Novartis-partnered Conatus to lay off 40% of its staff and begin looking for strategic alternatives.